AEON Biopharma AEON 深 滬
等待開盤 08-22 09:30:00 美东时间
0.1805
-0.013
-6.53%
華盛通- 最 高0.2074
- 今 開0.1977
- 成交量 143.30万股
- 最 低 0.1797
- 昨 收 0.1931
- 總市值 9003.843595
- 52周最高 1.45
- 市盈率 靜 --
- 換手率 2872.83%
- 52周最低 0.1772
- 委 比 0.00%
- 總股本 4.99万
- 歷史最高 1236.24
- 量 比 0.28
- 振 幅 14.34%
- 歷史最低 0.1772
- 每 手 1
- 風險率 0.26%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多AEON Reports Expanded Structural Data Supporting Molecular Similarity of ABP-450 to BOTOX®
AEON Biopharma announced progress in ABP-450's development as a BOTOX biosimilar, achieving 98% sequence coverage with 100% amino acid identity and confirming the critical C430-C454 disulfide bond. FDA feedback from an upcoming Type 2b meeting will guide future clinical studies, supporting the molecule's potential for full U.S. market entry.
08-19 12:00
AEON Biopharma Regains NYSE American Compliance
AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, today announced that it has received written notice from NYSE American LLC ("NYSE Amer...
08-04 04:22
AEON Biopharma Presents New Analytical And Functional Data Supporting Biosimilarity Of ABP-450 To BOTOX At 68th Annual Scientific Meeting Of AHS
AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry,
06-04 19:13
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Sunshine Biopharma (NASDAQ:SBFM) shares rose 94.0% to $0.55 during Mon...
05-19 01:05
AEON Biopharma Q1 EPS $(0.29) Misses $(0.13) Estimate
AEON Biopharma (AMEX:AEON) reported quarterly losses of $(0.29) per share which missed the analyst consensus estimate of $(0.13) by 141.67 percent. This is a 112.72 percent decrease over earnings of $2.28 per share from
05-15 04:41
AEON Biopharma Q4 EPS $(3.72)
AEON Biopharma (AMEX:AEON) reported quarterly losses of $(3.72) per share. This is a 199.2 percent decrease over earnings of $3.75 per share from the same period last year.
03-31 04:34
AEON Biopharma Announces Feedback From FDA Following Biosimilar BPD Type 2a Meeting; Co Plans To Request BPD Type 2b Meeting With FDA In 2026 To Discuss Development Of ABP-450 As Biosimilar To BOTOX
FDA provided constructive feedback on Company's analytical similarity strategy under the 351(k) biosimilar pathway Company continues to execute its analytical program and plans to request a BPD Type 2b meeting with
03-25 20:06
AEON Biopharma Names John Bencich As CFO
AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX® (onabotulinumtoxinA) to achieve accelerated and full-label
03-10 04:13
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers IO Biotech (NASDAQ:IOBT) stock increased by 76.7% to $0.37 during Thur...
01-23 01:05
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Athira Pharma (NASDAQ:ATHA) stock increased by 30.6% to $5.4 during Th...
2025-12-18 20:05
